Hepion PharmaceuticalsHEPA -14.29% 9-Day RSI is 45.51 as of Jul. 13, 2026. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Hepion Pharmaceuticals ranks better than 62.94% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Hepion Pharmaceuticals 9-Day RSI Related Terms
HEPA vs AXIM, ZVSA, ISCO: 9-Day RSI Comparison
For the Biotechnology subindustry, Hepion Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hepion Pharmaceuticals 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Hepion Pharmaceuticals's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hepion Pharmaceuticals (HEPA) has a 9-Day RSI of 45.51 as of Jul. 13, 2026. According to the industry distribution chart, Hepion Pharmaceuticals ranks #527 out of 1422 companies in the Biotechnology industry, placing it in the top 37.1%.
Is Hepion Pharmaceuticals' 9-Day RSI too high?
Hepion Pharmaceuticals' current 9-Day RSI is 45.51. The Biotechnology industry median 9-Day RSI is 50.12. Hepion Pharmaceuticals' value of 45.51 is 9.2% below this industry median. Based on the distribution chart, Hepion Pharmaceuticals ranks #527 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint.
How does Hepion Pharmaceuticals' 9-Day RSI compare to AXIM and ZVSA?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #527 out of 1422 companies for 9-Day RSI. This puts Hepion Pharmaceuticals in the upper half of its industry. The industry median 9-Day RSI is 50.12. Hepion Pharmaceuticals' value of 45.51 is 9.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hepion Pharmaceuticals's current 9-Day RSI of 45.51 is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hepion Pharmaceuticals's current 9-Day RSI is 45.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (HEPA) has a current 9-Day RSI of 45.51. The current 9-Day RSI is 45.51 and 9.2% below the Biotechnology industry median of 50.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Hepion Pharmaceuticals (HEPA), the current 9-Day RSI is 45.51 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HEPA has been successfully added to your